[1]
|
T. Tanaka, K. Shimada, K. Yamamoto, Y. Hirooka, et al. “Retrospective Analysis of Primary Gastric Diffuse Large B Cell Lymphoma in the Rituximab Era: A Multicenter Study of 95 Patients in Japan,” Annals of Hematology, Vol. 91, No. 3, 2012, pp. 383-390.
doi:10.1007/s00277-011-1306-0
|
[2]
|
A. Aviles, C. Castaneda, S. Cleto, N. Neri, et al., “Rituximab and Chemotherapy in Primary Gastric Lymphoma,” Cancer Biotherapy & Radiopharmaceuticals, Vol. 24, No. 1, 2009, pp. 25-28.
doi:10.1089/cbr.2008.0507
|
[3]
|
S. Wohrer, A. Puspok, J. Drach, M. Hejna, et al., “Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Treatment of Early-Stage Gastric Diffuse Large B-Cell Lymphoma,” Annals of Oncology, Vol. 15, No. 7, 2004, pp. 1086-1090.
doi:10.1093/annonc/mdh261
|
[4]
|
M. C. Chang, M. J. Huang, Y. W. Su, et al., “Clinical Outcome of Primary Gastric Lymphoma Treated with Chemotherapy Alone or Surgery Followed by Chemotherapy,”Journal of the Formosan Medical Association, Vol. 105, No. 3, 2006, pp. 194-202.
doi:10.1016/S0929-6646(09)60305-3
|
[5]
|
P. G. Isaacson, “Gastrointestinal Lymphoma,” Human Pathology, Vol. 25, 1994, pp. 1020-1029.
doi:10.1016/0046-8177(94)90060-4
|
[6]
|
T. Yoshino, K. Omonishi, K. Kobayashi, T. Mannami, et al., “Clinicopathological Fearture of Mucosa Associated Lymphoid Tissue (MALT) Lymphoma: High Grade Transformation and Comparison with Diffuse Large B Cell Lymphoma without MALT Lymphoma Features,” Journal of Clinical Pathology, Vol. 53, 2000, pp. 187-190.
doi:10.1136/jcp.53.3.187
|
[7]
|
E. S. Jaffe, N. L. Harris, H. Stein and J. W. Vardiman, “World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues,” IARC Press, Lyon, Vol. 2001.
|
[8]
|
F. d’Amore, H. Brinker, J. Gronbak, et al., “Non-Hodgkin’s Lymphoma of the Gastrointestinal Tract: A Population-Based Analysis of Incidence, Geographic Distribution, Clinicopathological Presentation, Features, and Prognosis,” Journal of Clinical Oncology, Vol. 12, No. 8, 1994, pp. 1673-1684.
|
[9]
|
J. Huang, W. Jiang, R. Xu, H. Huang, et al., “Primary Gastric Non-Hodgkin’s Lymphoma in Chinese Patients: Clinical Characteristics and Prognostic Factors,” BMC Cancer, Vol. 10, 2012, p. 358.
doi:10.1186/1471-2407-10-358
|
[10]
|
K. Mushoff, “Klinische Stadieneineteilung der Nicht-Hodgkin’s Lymphoma,” Strahlentherapie und Onkologie, Vol. 153, 1977, pp. 218-221.
|
[11]
|
A. Rohatiner, F. d’Amore, B. Coiffier, et al., “Report on a Workshop Convened to Discuss the Pathological and Staging Classifications of Gastrointestinal Tract Lymphoma,” Annals of Oncology, Vol. 5, No. 5, 1994, pp. 397-400.
|
[12]
|
G. Salles, R. Herbrecht, H. Tilly, et al., “Aggressive Primary Gastrointestinal Lymphomas: Review of 91 Patients Treated with the LNH-84 Regimen. A Study of the Group d’Etude des Lymphomes Agressifs,” American Journal of Medicine, Vol. 90, No. 1, 1991, pp. 77-84.
doi:10.1016/0002-9343(91)90509-V
|
[13]
|
M. Raderer, J. Valencak, C. ?sterreicher, et al., “Chemotherapy for the Treatment of Patients with Primary High Grade Gastric B-cell Lymphoma of Modified Ann Arbor Stages IE and IIE,” Cancer, Vol. 88, No. 9, 2000, pp. 1979-1985.
doi:10.1002/(SICI)1097-0142(20000501)88:9<1979::AID-CNCR1>3.0.CO;2-L
|
[14]
|
M. H. Maor, W. S. Valesquez, L. M. Fuller, et al., “Stomach Conservation in Stage IE and IIE Gastric Non-Hodgkin’s Lymphoma,” Journal of Clinical Oncology, Vol. 8, No. 2, 1990, pp. 266-271.
|
[15]
|
M. H. Shiu, L. Z. Nisce, A. Pinna, et al., “Recent Results of Multimodal Therapy of Gastric Lymphoma,” Cancer, Vol. 58, No. 7, 1986, pp. 1389-1399.
doi:10.1002/1097-0142(19861001)58:7<1389::AID-CNCR2820580702>3.0.CO;2-Y
|
[16]
|
F. A. Sheperd, W. K. Evans, G. Kutas, et al., “Chemotherapy Following Surgery for Stage IE and IIE Non-Hodgkin’s Lymphoma of the Gastrointestinal Tract,” Journal of Clinical Oncology, Vol. 6, No. 2, 1988, pp. 253-260.
|
[17]
|
M. K. Gospodarowicz, S. B. Sutcliffe, R. M. Clark, et al., “Outcome Analysis of Localized Gastrointestinal Lymphoma Treated with Surgery and Postoperative Irradiation,” International Journal of Radiation Oncology, Biology and Physics, Vol. 19, No. 6, 1990, pp. 1351-1355.
doi:10.1016/0360-3016(90)90343-I
|
[18]
|
C. Rosen, J. A. Heerden, L. K. Martin, et al., “Is an Aggressive Surgical Approach to the Patient with Gastric Lymphoma Warranted?” Annals of Surgery, Vol. 205, No. 6, 1987, pp. 634-640.
doi:10.1097/00000658-198706000-00004
|
[19]
|
M. S. Hockey, J. Powel, J. Crocker, et al., “Primary Gastric Lymphoma,” British Journal of Surgery, Vol. 74, No. 6, 1987, pp. 483-487. doi:10.1002/bjs.1800740620
|
[20]
|
R. J. Schwarz, J. M. Conners, N. Schmidt, et al., “Diagnosis and Management of Stage IE and Stage IIE Gastric Lymphomas,” The American Journal of Surgery, Vol. 165, No. 5, 1993, pp. 561-565.
doi:10.1016/S0002-9610(05)80435-0
|
[21]
|
E. D. Durr, J. A. Bonner, J. G. Strickler, et al., “Management of Stage IE Primary Gastric Lymphoma,” Acta Haematologica, Vol. 94, No. 2, 1995, pp. 59-68.
doi:10.1159/000203975
|
[22]
|
S. S. Yoon, D. G. Coit, C. S. Portlock, et al., “The Diminishing Role of Surgery in the Treatment of Gastric Lymphoma,” Annals of Surgery, Vol. 240, No. 2004, pp. 28-37. doi:10.1097/01.sla.0000129356.81281.0c
|
[23]
|
A. Avilés, M. J. Nambo, N. Neri, et al., “The Role of Surgery in Primary Gastric Lymphoma: Results of a Controlled Clinical Trial,” Annals of Surgery, Vol. 240, No. 1, 2004, pp. 44-50.
doi:10.1097/01.sla.0000129354.31318.f1
|
[24]
|
D. de Jong, B. M. P. Aleman, B. G. Taal, et al., “Controversies and Consensus in the Diagnosis, Work-Up and Treatment of Gastric Lymphoma: An International Survey,” Annals of Oncology, Vol. 10, No. 3, 1999, pp. 275-280. doi:10.1023/A:1008392022152
|
[25]
|
T. P. Miller, S. Dahlberg, J. R. Cassady, et al., “Chemotherapy Alone Compared Chemotherapy Plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin’s Lymphoma,” The New England Journal of Medicine, Vol. 339, 1998, pp. 21-26.
doi:10.1056/NEJM199807023390104
|
[26]
|
W. P. Sheridan, G. Medley, G. N. Brodie, “Non-Hodgkin’s Lymphoma of the Stomach: A Prospective Pilot Study of Surgery plus Chemotherapy in Early and Advanced Disease,” Journal of Clinical Oncology, Vol. 3, No. 4, 1985, pp. 495-500.
|
[27]
|
F. A. Shepherd, W. K. Evans, G. Kutas, et al., “Chemotherapy Following Surgery for Stages IE and IIE Non-Hodgkin’s Lymphoma of the Gastrointestinal Tract,” Journal of Clinical Oncology, Vol. 6, No. 2, 1988, pp. 253-260.
|
[28]
|
D. C. Cooper, R. Doria, E. Salloum, et al., “Primary Gastrointestinal Lymphomas,” Gastroenterologist, Vol. 4, 1996, pp. 54-64.
|
[29]
|
A. Ruskoné-Fourmestraux, P. Aegerter, A. Delmer, et al., “Primary Digestive Tract Lymphoma: A Prospective Multicentric Study of 91 Patients-Group d’Etude des Lymphoma Digestifs,” Gastroenterology, Vol. 105, No. 6, 1993, pp. 1662-1671.
|
[30]
|
P. G. Gobbi, P. Dionigi, F. Barbieri, et al., “The Role of Surgery in the Multimodal Treatment of Primary Gastric Non-Hodgkin’s Lymphoma: A Report of 76 Cases and Review of the Literature,” Cancer, Vol. 65, No. 11, 1990, pp. 2528-2536.
doi:10.1002/1097-0142(19900601)65:11<2528::AID-CNCR2820651123>3.0.CO;2-W
|
[31]
|
G. Bellesi, A. Alterini, A. Messori, et al., “Combined Surgery and Chemotherapy for the Treatment of Primary Gastrointestinal Intermediate- or High-Grade Non-Hodgkin’s Lymphomas,” British Journal of Cancer, Vol. 60, 1989, pp. 244-248. doi:10.1038/bjc.1989.262
|
[32]
|
C. Tondini, F. Giardini, P. Bezztti, et al., “Combined Modality Treatment for Primary Gastrointestinal Non-Hodgkin’s Lymphoma: The Milan Cancer Institute Experience,” Annals of Oncology, Vol. 4, No. 10, 1993, pp. 831-837.
|
[33]
|
V. L. Rackner, J. A. Thirlby, “Ryan Role of Surgery in Multimodality Therapy for Gastrointestinal Lymphoma,” The American Journal of Surgery, Vol. 161, No. 5, 1991, pp. 570-575. doi:10.1016/0002-9610(91)90902-P
|
[34]
|
A. Ruskoné-Fourmestraux, P. Aegerter, A. Delmer, et al., “Primary Digestive Tract Lymphoma: A Prospective Multicentric Study of 91 Patients-Group d’Etude des Lymphoma Digestifs,” Gastroenterology, Vol. 105, No. 6, 1993, pp. 1662-1671.
|
[35]
|
H. T. Liu, C. Hsu, C. L. Chen, et al., “Chemotherapy Alone versus Surgery Followed by Chemotherapy for Stage I/IIE Large-Cell Lymphoma of the Stomach,” American Journal of Hematology, Vol. 64, No. 3, 2000, pp. 175-179.
doi:10.1002/1096-8652(200007)64:3<175::AID-AJH6>3.0.CO;2-7
|
[36]
|
B. Coiffier, C. Gisselbrecht, R. Herbrecht, et al., “LNH-84 Regimen: A Multicentric Study of Intensive Chemotherapy in 737 Patients with Aggressive Malignant Lymphoma,” Journal of Clinical Oncology, Vol. 7, 1989, pp. 1018-1026.
|
[37]
|
S. Nakamura, T. Matsumoto, M. Iida, et al., “Primary Gastric Lymphoma in Japan: A Clinicopathologic Analysis of 455 Patients with Special Reference to Its Time Trends,” Cancer, Vol. 97, No. 10, 2003, pp. 2462-2473.
doi:10.1002/cncr.11415
|
[38]
|
C. L. Ho, A. T. Hsieh, M. S. Dai, et al., “Non-Hodgkin’s Lymphoma of the Stomach: Treatment Outcomes for 57 Patients over a 20-Year Period,” Journal of the Chinese Medical Association, Vol. 68, No. 1, 2005, pp. 11-15.
doi:10.1016/S1726-4901(09)70125-X
|
[39]
|
M. Binn, A. Rouskoné-Fourmestraux, E. Lepage, et al., “Surgical Resection plus Chemotherapy versus Chemotherapy Alone: Comparison of Two Strategies to Treat Diffuses Large B-Cell Lymphoma,” Annals of Oncology, Vol. 14, No. 12, 2003, pp. 1751-1757.
doi:10.1093/annonc/mdg495
|
[40]
|
J. C. Vaillant, A. Ruskoné-Fourmestraux, P. Aegerter, et al., “Management and Long-Term Results of Surgery for Localized Gastric Lymphomas,” The American Journal of Surgery, Vol. 179, No. 3, 2000, pp. 216-222.
doi:10.1016/S0002-9610(00)00295-6
|
[41]
|
B. P. Koch, F. del Valle, W. E. Berdel, et al., “Primary Gastrointestinal Non-Hodgkin’s Lymphoma: II. Combined Surgical and Conservative or Conservative Management Only in Localized Gastric Lymphoma-Results of the Prospective German Multicenter Study GIT NHL 01/92,” Journal of Clinical Oncology, Vol. 19, No. 18, 2001, pp. 3874-3878.
|
[42]
|
Y. Lv, X. N. Wang, H. Liang, “Clinical Analysis of 200 Patients with Primary Gastric Lymphoma,” Zhonghua Wei Chang Wai Ke Za Zhi, Vol. 15, No. 2, 2012, pp. 157-160.
|
[43]
|
F. Sel?ukbiricik, D. Tural, O. Elicin, S. Berk, et al., “Primary Gastric Lymphoma: Conservative Treatment Modality is Not Inferior to Surgery for Early-Stage Disease,” ISRN Oncology, Vol. 2012, 2012, p. 951816.
doi:10.5402/2012/951816
|
[44]
|
B. Coiffier, C. Gisselbrecht, A. Bosly, et al., “Ten Years Follow-Up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma,” ASH 2009.
|
[45]
|
A. Ruskoné-Fourmestraux, A. Lavergne, P. H. Aegerter, F. Megraud, et al., “Predictive Factors for Regression of Gastric MALT Lymphoma after Anti-Helicobacter Pylori Treatment,” Gut, Vol. 48, No. 3, 2001, pp. 297-303.
doi:10.1136/gut.48.3.297
|
[46]
|
L. T. Chen, J. T. Lin, J. J. Tai, G. H. Chen, et al., “Long-Term Results of Anti-Helicobacter Pylori Therapy in Early-Stage Gastric High-Grade Transformed MALT Lymphoma,” Journal of the National Cancer Institute, Vol. 97, No. 18, 2005, pp. 1345-1353.
doi:10.1093/jnci/dji277
|
[47]
|
S. Nakamura, T. Matsumoto, H. Suekane, M. Takeshita, et al., “Predictive Value of Endoscopic Ultrasonography for Regression of Gastric Low Grade and High Grade MALT Lymphomas after Eradication of Helicobacter Pylori,” Gut, Vol. 48, No. 4, 2001, pp. 454-60.
doi:10.1136/gut.48.4.454
|
[48]
|
W. W. Ng, C. P. Lam, W. K. Chau, A. Fen-Yau Li, et al., “Regression of High-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma with Helicobacter Pylori after Triple Antibiotic Therapy,” Gastrointestinal Endoscopy, Vol. 51, No. 1, 2000, pp. 93-96.
doi:10.1016/S0016-5107(00)70399-3
|
[49]
|
L. Cavanna, R. Pagani, P. Seghini, et al., “High Grade B-Cell Gastric Lymphoma with Complete Pathologic Remission after Eradication of Helicobacter Pylori Infection: Report of a Case and Review of the Literature,” World Journal of Surgical Oncology, Vol. 6, 2008, p. 35
|
[50]
|
B. Cheson, M. Rummel Bendamustine, “Rebirth of an Old Drug,” Journal of Clinical Oncology, 2009, pp. 1492-1501.
|
[51]
|
M. Rummel, E. Sahah, Al-Batran et al., “Bedamustine plus Rituximab is Effective as Favorable Toxicity Profile in the Treatment of Mantle Cell and Low Grade Non-Hodgkin’s Lymphoma,” Journal of Clinical Oncology, Vol. 23, No. 15, 2005, pp. 3383-3389.
|
[52]
|
K. Dunleavy, S. Pittluga, M. S. Czuczman, et al., “Differential Efficacy of Bortezomib plus Chemotherapy within Molecular Subtype of Diffuse Large B Cell Lymphoma,” Blood, Vol. 113, No. 24, 2009, pp. 6069-6076.
|
[53]
|
F. J. Hernandez-Ilizaliturri, G. Deeb, P. L. Zinzani, et al., “Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B Cell Lymphoma in Non-Germinal Center B-Cell-Like Than in Germinal Center B-Cell-Like Phenotype,” Cancer, Vol. 117, No. 22, 2011, pp. 5058-5066.
|